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Abstract 
Breast cancer is the cancer that most commonly affects women worldwide. This type of cancer is 
genetically complex, but is strongly linked to steroid hormone signalling systems. Because 
microRNAs act as translational regulators of multiple genes, including the steroid nuclear 
receptors, single nucleotide polymorphisms (SNPs) in microRNAs genes can have potentially 
wide-ranging influences on breast cancer development. Thus, this study was conducted to 
investigate the relationships between six SNPs (rs6977848, rs199981120, rs185641358, 
rs113054794, rs66461782, and rs12940701) located in four miRNA genes predicted to target the 
estrogen receptor (miR-148a, miR-221, miR-186, and miR-152) and breast cancer risk in 
Caucasian Australian women. By using high resolution melt analysis (HRM) and polymerase 
chain reaction- restriction fragment length polymorphism (PCR-RFLP), 487 samples including 
225 controls and 262 cases were genotyped. Analysis of their genotype and allele frequencies 
indicated that the differences between case and control populations was not significant for 
rs6977848, rs66461782, and rs12940701 because their p-values are 0.81, 0.93, 0.1 which are all 
above the threshold value (p=0.05). Our data thus suggests that these SNPs do not affect breast 
cancer risk in the tested population. In addition, rs199981120, rs185641358, and rs113054794 
could not be found in this population, suggesting that these SNPs do not occur in Caucasian 
Australians. 
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1. Introduction 
Breast cancer has become the most common cancer and the major cause of death among women 
worldwide. According to the WHO, about 1.38 million new cases of breast cancer, roughly 
690,000 for developed and developing countries, were diagnosed in 2008. Specifically in 
Australia, breast cancer is the second most diagnosed cancer after prostate cancer for both sexes 
but it has the highest incidence among cancers in women only (Ferlay, Shin et. al. 2010) 
Breast cancer occurs when cells in a woman's breast tissue start to grow abnormally. Unlike 
many other diseases which have a single cause, such as infectious diseases, most cancers are 
usually consequences of the interaction between numerous factors comprising both genetic 
characteristics and lifestyle factors. Lately, researchers have begun to notice the role of micro 
RNA (miRNAs) and their polymorphisms in breast cancer. MicroRNAs (miRNAs) are small 
(usually from 18 to 25 nucleotide long), single stranded, and noncoding RNAs. These small 
miRNAs play crucial roles in a wide range of biological and pathological process such as cell 
cycle, differentiation, development, and metabolism as well as many diseases like cancer (Lu, 
Getz et al. 2005), (Heneghan, Miller et al. 2009). Specifically, miRNAs can regulate gene 
expression at the posttranscriptional level by repressing translation of protein coding genes, or 
cleaving target mRNAs, depending on the degree of complementarity between the miRNA and 
its target mRNA (Jackson and Standart 2007). It is estimated that miRNAs regulate more than 
60% of the human genome and more than 1000 human miRNAs have been found (Friedman, 
Farh et al. 2009). It has been found that the abnormal expression of miRNAs may link to cancer 
risk. Oncogenic miRNAs, commonly termed oncomirs, are usually upregulated in cancer cells. 
Their targets are tumor suppressor genes and increases in their expression may lead to impeding 
the expression of those genes. Some examples are miR-21, miR-96, miR-182 (Si, Zhu et al. 
2007), (Guttilla and White 2009). In contrast, tumor suppressor miRNAs (such as miR-205, 
miR-27b, miR-17-5p) often express at lower levels in cancer cells than in normal cells (Iorio, 
Ferracin et al. 2005), (Tsuchiya, Nakajima et al. 2006), (Hossain, Kuo et al. 2006). Because these 
miRNAs act on genes that promote tumorigenesis (oncogenes), a decrease in their expression 
level will result in an increase in oncogene effects and development of cancer cells (Zhang, Pan 
et al. 2007). One of the causes of this dysregulation of miRNA expression is variations or single 
nucleotide polymorphisms (SNPs) in those genes (Slaby, Bienertova-Vasku et al. 2012). 
In this study, miR-148a, miR-221, miR-186, and miR-152 were chosen to examine the 
relationship between their polymorphisms and breast cancer risk. These miRNAs were chosen 
due to their function of targeting the estrogen receptor, which plays an important role in breast 
cancer development and progression. In addition, many studies have reported that while miR-
148a and miR-152 were down regulated in breast cancer cells, miR-221 and miR-186 were up-
regulated, indicating that they may be actively involved in breast cancer progression (Yu, Li et 
al. 2011), (Xu, Jiang et al. 2013), (Nassirpour, Mehta et al. 2013), (Zhou, Qi et al. 2008). Six 
single nucleotide polymorphisms (SNPs): rs6977848, rs199981120, rs185641358 in miR-148a; 
rs113054794 in miR-221; rs66461782 in miR-186 and rs12940701 in miR-152 were tested in 
this research.  
2. Materials and methods 
2.1 Study population 
This project was conducted using a Caucasian sporadic breast cancer population which was 
available at the Genomics Research Centre (GRC), Institute for Health and Biomedical 
Innovation, Queensland University of Technology, Australia. The population was comprised of 
262 cases from female Caucasian patients suffering from sporadic breast cancer. Sporadic nature 
of breast cancer was determined by eliminating any individual with a first degree relative with 
breast cancer, or any family history of other cancers. Controls (225 total) were from healthy 
women and were matched to cases for sex, ethnicity and age within five years. No other breast 
cancer risk factors were controlled for. Controls were deemed ineligible if they had any family 
history of any cancer, including a first degree relative with breast cancer. All samples came from 
Caucasian women and the average age was 57 and 57.5 years for cases and controls, 
respectively.  
2.2 SNP Selection and Genotyping 
SNPs for the study were selected by identifying candidate miRNAs using the target prediction 
search at the microRNA.org database (http://www.microrna.org/microrna/searchGenes.do). 
Candidate miRNAs were selected based on strong mirSVR and PhastCons scores for binding to 
the estrogen receptor alpha, one of the main drivers of breast cell proliferation. Candidate 
miRNAs were then examined using the Gene database at NCBI 
(http://www.ncbi.nlm.nih.gov/gene/) to identify the presence of SNPs within them.  
In order to detect candidate SNPs in this study, four sets of primers were designed using Primer3 
(http://frodo.wi.mit.edu/) and checked for specificity through BLAST 
(http://blast.ncbi.nlm.nih.gov). SNPs in miR-148a, miR-221, miR-186 were genotyped using 
high resolution melt (HRM) analysis on a RotorGene-Q (Qiagen, Australia). When initial 
experiments indicated that HRM could not provide reliable genotypes for the SNP in miR-152, 
restriction fragment length polymorphism (PCR-RFLP) was instead used to obtain genotypes. 
Primers and amplicon characteristics are summarized in Table 1. 
PCR amplification and HRM analyses were carried out in a 16.5µL reactions containing: 2µL of 
20ng/µL genomic DNA, 2µL of 10µM each forward and reverse primers, 2.4µL of 5X GoTaq 
Buffer, 0.8µL of 5µM dNTPs, 0.05µL of 5Units/µL GoTaq (Promega, Australia), 0.9µL of 5µM 
Syto-9 dye, 2.1µL of 25mM MgCl2 and 4.25µL dH2O (for miR-148a and miR-221); or 2.3 µL of 
25mM MgCl2 and 4.05µL dH2O for miR-186. PCR conditions for amplifying miR-148a and 
miR-221 were: 95
o
C for 2 minutes, followed by 40 cycles of 95
o
C for 15 seconds, 61
o
C for 15 
seconds and 72
o
C for 30 seconds. Melting analysis was carried out between 78
o
C and 88
o
C with 
0.1
o
C increments. The PCR protocol for miR-186 was similar but melting analysis was carried 
out from 68
o
C to 87
o
C, also with 0.1
o
C increments. One negative control and positive controls of 
each genotype (confirmed by sequencing) were included in each run to ensure the accuracy of 
genotyping. Each sample was performed in duplicate. 
The PCR-RFLP reaction was prepared slightly differently with a final volume of 25µL: 1µL of 
each forward and reverse primer at 10µM, 5µL GoTaq Buffer (5x), 0.8µL of dNTPs (5µM), 
0.1µL of GoTaq Flexi DNA polymerase (Promega, Australia), 2µL of DNA (20ng/µL), the 
1.8µL of 25mM MgCl2, and 13.3 µL dH2O. By using a Veriti Thermal Cycler (Applied 
Biosystems), the PCR reaction was run using the following protocol: 95
o
C for 5 minutes, 40 
cycles of 95
o
C for 15 seconds, 65
o
C for 15s, 72
o
C for 30 seconds, 72
o
C for 5 minutes, and hold 
at 4
o
C. Again, negative control reactions were also set up and performed alongside the 
experimental PCR. Products were checked by performing gel electrophoresis at 90V for 30 
minutes on a 2% agarose gel. Restriction reactions were carried out by adding 1µL of buffer, 
0.1µL of DdeI (New England Biolabs, Australia), and 8.9µL of PCR product in a PCR tube and 
incubating at 37
o
C for 60 minutes and holding at 4
o
C. The results were then obtained by running 
gel electrophoresis at 70V for 60 minutes with a 4% agarose gel. A positive control for complete 
digestion (genotype TT) was included in each restriction reaction to verify cutting efficiency. 
Table 1 Here 
2.3 Analysis 
Data from HRM was compared to postitive control samples included in each run (where 
available). Samples where duplicates deviated from the positive control melt pattern by more 
than 0.125°C were subject to repeat to confirm genotype, with repeatedly ambiguous samples 
removed from consideration in analysis. RFLP samples showing evidence of incomplete 
digestion were repeated, with samples showing repeated ambiguous digestion eliminated from 
the analysis. Data obtained from HRM and PCR-RFLP, analysis was tabulated into genotypes 
and allele frequencies. Analysis carried out using a Chi-square test for genotype and allele 
frequencies using SPSS software version 20. Adherence to the Hardy-Weinberg equilibrium was 
also tested for each SNP and population using manual calculation.  
  
3. Results 
3.1 miR-221 
After obtaining melting data, 115 samples genotyped for miR-221 showed similar curves which 
were closely parallel to one another (figure 1). Thus, all samples appeared to have the same 
genotype which is homozygous CC, the genotype of the positive control sample. This also 
implies that SNP rs113054794 is either not present or highly rare in Caucasians. 
 
Figure 1 Here 
 
3.2 miR-148a 
Despite obtaining optimal condition for the PCR reaction, only 427/487 samples were able to 
produce data for miR-148a, including 204 controls and 223 cases. Among the three targeted 
SNPs on this miRNA, only the presence of SNP rs6977848 could be detected. Based on our data, 
SNPs rs199981120 and rs185641358 occur in Caucasians at a very low frequency, or not at all, 
because all tested samples showed the AA genotype for both SNPs, containing only the ancestral 
A allele. This was confirmed along with variant genotypes in rs6977848 by sequencing 8 
samples from the populations selected at random, in addition to the positive control samples. 
A typical HRM result is shown in figure 2. Table 2 presents the genotyping results as well as 
statistical analysis for rs6977848 in control and case groups. Both populations proved to be in 
Hardy Weinberg equilibrium (p=0.07 and 0.6 for cases and controls, respectively). Although the 
TT genotype was slightly more common in the breast cancer population than in the control 
population, Chi-square analysis of this data showed that there was no significant difference 
between these two groups both for genotypes (χ2= 0.82, p=0.67) and alleles (χ2= 0.06, p= 0.81). 
Thus there is not a significant association between this SNP and breast cancer development. 
 
Figure 2 Here 
 
Table 2 Here 
3.3 miR-186 
For miR-186, 393/487 samples were genotyped, including 187 controls and 206 cases. An 
example HRM result with three different genotypes can be seen in figure 3. The results obtained 
from HRM and Chi-square analysis are summarized in Table 3. HWE p values were 0.73 and 
0.62, indicating that both control and case groups were in Hardy Weinberg equilibrium. Again, 
the TT genotype in cases seems to appear more frequently than in controls but with the 
significance higher than the  of 0.05, statistical analysis indicated that this SNP does not have a 
significant association with breast cancer risk. 
 
Figure 3 Here 
 
Table 3 Here 
3.4 miR-152 
Figure 4 illustrates RFLP results for miR-152. Table 4 shows the summarized results obtained 
after RFLP genotyping. Unlike the two other SNPs, the non-ancestral allele (T allele) seems to 
appear more often in controls than in cases. HWE p values were calculated for both cases and 
controls and both p values (HWE pcase= 0.95, HWE pcontrol= 0.15) were above 0.05 threshold 
value, indicating that both populations are in Hardy-Weinberg equilibrium. Despite the clear 
increase of T alleles in the controls, χ2 analysis of those frequencies showed an insignificant 
difference between cases and controls since both genotypes (χ2= 3.79, p=0.15) and alleles (χ2= 
2.73, p= 0.1) were both greater than the . Thus, this polymorphism was also not associated with 
sporadic breast cancer. 
 
Figure 4 Here 
Table 4 here 
 
In addition, when comparing control genotype frequencies for those SNPs with those in a 
European population (HapMap and 1000 genome project) it was found that these populations 
corresponded closely or were not significantly different (This can be seen in Table 5). This 
would indicate that genotyping for these SNPs was accurate. 
 
Table 5 Here 
 
4. Discussion 
In this study, we examined the genotypes frequency of six SNPs in four miRNAs predicted to 
target the estrogen receptor alpha, specifically miR-148a, miR-221, miR-186, and miR-152, 
using HRM and RFLP methods. Of the SNPs genotyped, rs6977848, rs66461782, and 
rs12940701 were found to not show significant association with sporadic breast cancer risk. In 
addition, the SNPs rs199981120, rs185641358 and rs113054794 could not be detected in cases 
or controls, indicating that these SNPs are non-polymorphic or highly rare in Caucasian 
populations. 
Previous work by our laboratory and others has shown that SNPs in micro-RNAs and their 
binding sites on genes have influence on breast cancer risk (Kontorovich et al. 2010, Pastrello et 
al. 2010, Smith et al. 2012, Wang et al. 2011, Zhang et al. 2011, Zheng et al. 2011). This 
includes both sporadic and familial forms, where polymorphisms in miRNAs have been found to 
alter the age of onset of tumours (Pastrello et al.2010). On the other hand, other studies have 
failed to show association with miRNA SNPs and breast cancer risk, such as the large study by 
Cattuci and colleagues, who examined a large association population consisting of German and 
Italian women with breast cancer, finding no association between SNPs in miR-146a, miR196a2 
and miR-499 and breast cancer risk (Cattuci et al. 2010). It seems likely, therefore, that the 
impact of a given SNP will depend heavily on its functional effects on the miRNA itself, and the 
degree to which the native miRNA affects the expression of cancer driving genes. 
Several previous research projects have been carried out to investigate the relationships between 
the miRNAs targeted by this research and breast cancer. Using Taqman real-time polymerase 
chain reaction, the expression of these miRNAs were measured and compared between normal 
and breast cancer cell lines.  By applying this method, Xu and colleagues found that miR-148a 
and miR-152 were dramatically down-regulated in breast cancer cells (p<0.05). A consistent 
result was also achieved when they tested breast cancer tissue. In addition, lower levels of miR-
148a and miR-152 were significantly correlated with breast cancer stage and breast cancer cases 
with lymph node metastasis (p<0.05) (Xu, Jiang et al. 2013). Meanwhile, miR-186 was found to 
be up-regulated in breast cancer cells as well as in cervical cancer cells (Zhou, Qi et al. 2008). 
Similarly, miR-221 was also up-regulated in breast cancer, especially in triple negative breast 
cancer cells (Nassirpour, Mehta et al. 2013). This would imply that the miRNAs tested in this 
study have effective roles in breast cancer development, though functional research on their 
effects is needed to determine precisely what function they perform in breast cancer pathogenesis 
and whether their predicted targeting of the estrogen receptor is responsible. 
This study is the first research that examines the effect of the targeted SNPs (rs6977848, 
rs199981120, rs185641358, rs113054794, rs66461782, and rs12940701) in these miRNAs in 
terms of breast cancer risk development. The results showed that the chosen single nucleotide 
polymorphisms in miR-148a (rs6977848), miR-186 (rs66461782) and miR-152 (rs12940701) 
were not associated with increased breast cancer risk. This implies that any aberrant expression 
of those miRNAs in breast cancer cells may be due to other SNPs at different loci or be caused 
by another effect, such as changes in DNA copy number in cancer cells or DNA methylation, 
which could also contribute to the different expression of the miRNAs observed in previous 
research. Similarly, it implies that these SNPs do not significantly affect the expression of the 
estrogen receptor in breast cancer, or that other factors allow the estrogen receptor to be 
expressed or function at unchanged levels, despite any difference in miRNA behavior these 
SNPs might cause. 
It may be, however, that these SNPs do affect the behavior of these miRNAs in some way 
significant to the progression of breast cancer, but that they do not affect risk of developing the 
disease. Due to the lack of research on the functional effects of these SNPs, the likelihood of 
their having effects after breast cancer initiation cannot be properly assessed. Thus, such research 
is a logical next step, and may be useful in understanding the role that these miRNAs play in 
breast cancer progression, even if they have no effect on risk of breast cancer initiation. Our 
population is also one of limited size, and it is possible that there is an effect of these SNPs on 
breast cancer risk, but that it is relatively weak or interacts with other risk factors, and we have 
insufficient power to detect it. Despite our agreement with previously obtained genotype 
frequencies from HapMap and 1000 Genomes data, further research using a larger population of 
cases and controls, preferably with further risk factor controls is advised. 
In addition, our study is the first to examine the SNPs rs113054794, rs199981120 and 
rs185641358 and their effect on breast cancer risk. These SNPs have been annotated in the NCBI 
SNP database, but no frequency data is currently available for them. Our results indicate that 
these SNPs are extremely rare in Caucasian populations, occurring at rates much lower than 1%. 
While these SNPs are likely to be insignificant for breast cancer risk in Caucasians, they may be 
significant factors in other populations and research to determine their frequency and breast 
cancer risk profile is worth undertaking. 
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Figures 
 
 
Figure 1: Example of Normalized melting curve for miR-221 SNP rs113054794. All curves have the 
same shape indicating that these samples have the same genotypes. 
  
 Figure 2: Example of Normalized melting curve for miR-148a SNP rs6977848. Three different genotypes 
(GG, GT, TT) were identified due to different curve shape. Homozygous samples produce standard S-
curves while heterozygotes show a flatter or multi-flexed curve.  
  
 Figure 3: Example of Normalized melting curve for miR-186 SNP rs66461782. Three different genotypes 
(AA, AT, TT) were identified due to different curve shape. Homozygous samples produce standard S-
curves while heterozygotes show a flatter or multi-flexed curve. 
  
 Figure 4: Example RFLP results for miR-152 SNP rs12940701. PC: positive control. The first lane is 
100bp ladder. PCR produces a single band of 170bp, which remains undigested in CC homozygous 
individuals (e.g. 1B, 1E). Heterozygous samples show three bands at 170bp, 100bp, and 70bp (e.g. 1C, 
1H). Samples with only 100bp and 70bp bands were homozygous TT (e.g. 6E, 7B).  
  
Tables 
 
Table 1: Primers and their melting temperature 
miR SNP Name Sequence (5’ → 3’) Tm Product 
size (bp) 
148a 
rs6977848 
rs199981120 
rs185641358 
miR148a_F 
miR148a_R 
CTGGCGTCTGGAGCACTG 
AGGAAGACAGCACGTTTGGT 
58.6 
56.9 
136 
221 rs113054794 
miR221_F 
miR221_R 
CCCAGCAGACAATGTAGCTG 
ACTTGCAAGCTGAACATCCA 
55.9 
55 
93 
186 rs66461782 
miR186_F 
miR186_R 
TTGACATTCACATGCTTCAGG 
CCTTTTGGGCTTTCTGGTTT 
59.7 
60.5 
153 
152 rs12940701 
miR152_F 
miR152_R 
TCTGTCATGCACTGACTGCTC 
GGGCATGCTTCTGGAGTCTA 
60.2 
60.4 
170 
 
  
Table 2: Statistical analysis for SNP rs6977848- miR-148a 
Genotypes GG GT TT G T 
HWE 
sig. 
Cases 38 92 93 168 278 
0.07 
223 (17.0%) (41.3%) (41.7%) (37.7%) (62.3%) 
Controls 32 93 79 157 251 
0.60 
204 (15.7%) (45.6%) (38.7%) (38.5%) (61.5%) 
Chi-Square 0.82 0.06 
 p-value 0.67 0.81 
  
  
Table 3: Statistical analysis for SNP rs66461782- miR-186 
Genotypes AA AT TT A T 
HWE 
sig. 
Cases 129 67 10 325 87 
0.73 
206 (62.6%) (32.5%) (4.9%) (78.9%) (21.1%) 
Controls 116 64 7 296 78 
0.62 
187 (62.0%) (34.2%) (3.7%) (79.1%) (20.9%) 
Chi-Square 0.37 0.01 
 p-value 0.83 0.93 
  
  
Table 4: Statistical analysis for SNP rs12940701- miR-152 
Genotypes CC CT TT C T 
HWE 
sig. 
Cases 120 94 18 334 130 
0.95 
232 (51.7%) (40.5%) (7.8%) (72.0%) (28.0%) 
Controls 87 100 18 274 136 
0.15 
205 (42.4%) (48.8%) (8.8%) (66.8%) (33.2%) 
Chi-Square 3.79 2.73 
 p-value 0.15 0.10 
  
  
Table 5: Genotype and allele frequencies for rs6977848, rs66461782, rs12940701 in study vs. 
HapMap/1000 Genomes data. 
   p-
value 
Genotyping result HapMap/1000genome 
miR-
148a 
rs6977848 
G 
T 
0.56 38.5% 
61.5% 
42.5% 
57.5% 
GG 
GT 
TT 
0.34 15.7% 
45.6% 
38.7% 
23.3% 
38.3% 
38.3% 
miR-186 rs66461782 
A 
T 
0.66 79.1% 
20.9% 
76.5% 
23.5% 
AA 
AT 
TT 
0.56 62.0% 
34.2% 
3.7% 
60.0% 
32.9% 
7.1% 
miR-152 rs12940701 
C 
T 
0.34 66.8% 
33.2% 
72.9% 
27.1% 
CC 
CT 
TT 
0.23 42.4% 
48.8% 
8.8% 
54.1% 
37.6% 
8.3% 
Data from http://www.ncbi.nlm.nih.gov and http://www.ensembl.org/index.html  
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